Cochlear Limited (ASX: COH) — Investment Research Report

3-Year / 5-Year Price Scenarios

Base EPS: $5.94 — FY25 statutory EPS was A$5.943; HY26 statutory EPS was A$2.469 and underlying EPS A$2.978. The valuation uses FY25 statutory EPS as a conservative normalized base.

0. Information Richness & AI Limitations

Grade A. Cochlear publishes detailed audited annual and interim reports, operating metrics and guidance. The latest published annual result by the 2026-07-31 cutoff was FY25; the newer HY26 interim result was published on 2026-02-13. FY26 full-year results were not yet published; a July 28 briefing notice is not a result. Confidence in reported facts is high, while long-range targets remain subjective.

1. Data & Cross-Validation

ASX Markit Digital reported A$119.97 on 2026-07-31 and market capitalisation of A$7.992B. Dividing by the quote implies about 66.63M shares; HY26 reported 65.54M diluted weighted-average shares, so the difference is consistent with timing and dilution. FY25 total revenue was A$2,343.1M, attributable profit A$388.9M and basic EPS A$5.943. HY26 total revenue was A$1,167.2M, attributable profit A$161.5M and basic EPS A$2.469; underlying profit was A$194.8M. HY26 sales revenue rose 1% to A$1,176.0M, implant units rose 6% to 27,016, while underlying profit fell 9%. Primary sources: Cochlear FY25 report and HY26 report. The ASX header is the independent live-price and market-cap cross-check.

2. Business Essence — Duan Yongping

One line: Cochlear designs, manufactures and supports implantable hearing systems that restore hearing, with a large installed base generating replacement, upgrade and service economics. Clinical outcomes, surgeon familiarity and reimbursement support customer value; R&D and manufacturing scale create operating leverage, although the business remains innovation- and quality-intensive.

3. Moat — Buffett

The moat combines brand trust, clinical evidence, regulatory approvals, surgeon and audiologist training, switching costs for recipients, global scale and a long-lived installed base. Services and upgrades add recurring economics. HY26 said Nucleus Nexa received positive professional and recipient reception and gained market share, but also noted increased competitor activity in Osia. The moat is wide and likely stable-to-widening if Nexa succeeds; it narrows if competitors match outcomes or Cochlear suffers a product-quality failure.

4. Reverse Thinking & Risks — Munger

| Failure path | Prob | Impact |\n|---|---|---|\n| Competitor product or reimbursement disruption | Med | High |\n| Product safety, quality or regulatory failure | Low-med | Very high |\n| Nexa contracting delays and lower-priced emerging-market mix | Med | Med |\n| FX volatility and sustained R&D investment compress margins | Med | Med |\n| A$120 valuation de-rates despite good execution | Med | Med-high |\n\nThe key disconfirming evidence is persistent unit-share loss, declining service attachment or repeated guidance cuts. HY26 already showed the tension: units grew 6%, but implant revenue was flat and underlying profit declined 9%.

5. Management — Duan Yongping + Buffett

Management continues to fund approximately 13% of sales in R&D, maintains a dividend policy targeting 70% of underlying profit, and launched Nexa while navigating contracting delays. HY26's A$2.15 interim dividend was 72% of underlying profit. This is sensible reinvestment for a medical-device leader; the main test is whether R&D converts into durable share and margin growth rather than perpetual expense.

6. Industry & Civilizational Trend — Li Lu

Hearing loss is a large, under-treated global clinical need. Aging populations, better diagnosis and improving awareness support a long runway, but reimbursement, surgery capacity and affordability constrain TAM conversion. Cochlear sits at the high-value clinical-device layer, where reliability matters more than low price. AI and consumer audio may improve screening and augmentation, but implant surgery and long-term clinical support remain specialised.

7. Valuation & Scenarios — Buffett + Duan

At A$119.97 and FY25 EPS of A$5.943, the stock trades near 20.2x trailing statutory EPS. The scenarios use a conservative normalized EPS base, explicit probability weights and terminal P/E assumptions. Three-year weighted target is A$143.85 (+19.9%); five-year weighted target is A$166.10 (+38.5%). Bull cases require successful Nexa adoption, sustained unit growth and a premium multiple. Bear cases assume share loss, margin pressure and multiple compression. These are analytical scenarios, not forecasts; FX, reimbursement and product outcomes are the largest uncertainties.

8. Decision Memo

Stance: Accumulate, not chase. A wide moat and long runway justify a core-quality rating, but valuation is not a large margin-of-safety entry. Buy zone: A$100–115 or a forward PE below 18x. Add when developed-market units and underlying profit reaccelerate. Sell or reassess after persistent market-share loss, quality/regulatory issues, or repeated guidance reductions. The thesis is invalidated by evidence that Cochlear's clinical and service advantages no longer translate into durable unit economics.

Four-Master Commentary

Buffett (analytical simulation): A high-return medical-device franchise with recurring service economics and a meaningful moat, but price discipline matters.\n\n> Munger (analytical simulation): Invert it: one product-quality event or sustained competitor share gain can destroy years of trust, so demand a margin of safety.\n\n> Duan Yongping (analytical simulation): The business is simple to admire—good product, repeat need, strong brand—but buy only when the price respects uncertainty.\n\n> Li Lu (analytical simulation): Aging and under-treated hearing loss provide a durable civilizational tailwind, while reimbursement and innovation determine how much of the TAM becomes cash flow.